Cardiff Oncology Reports Fourth Quarter and Full Year 2021 R

/PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a...

Related Keywords

United States , American , Heinz Josef Lenz , Acta Oncologica , Amy Jobe , Adam Schayowitz , Joyce Allaire , Eli Lilly , Erytech Pharma , Tod Smeal , Charles Monahan , Mark Erlander , Vicki Kelemen , Cardiff Oncology Inc , Crc Program , Prnewswire Cardiff Oncology Inc , Medicine Team Group Lead For Breast Cancer , Nasdaq , Exchange Commission , Pfizer , Lifesci Communications , Norris Comprehensive Cancer Center , Oncology Research Unit Of Pfizer , Pfizer Breakthrough Growth Initiative , Metastatic Colorectal Cancer , Cardiff Oncology , American Society , Pfizer Breakthrough Growth , Vice President , Medicine Team Group Lead , Breast Cancer , Colorectal Cancer , Scientific Advisory , Cancer Biology , Oncology Research Unit , Full Year , Lancet Oncol , Correspondence Lancet Oncol June , Private Securities Litigation Reform Act , Oncology Contact , Nc , Health Care Amp Hospitals , Medical Pharmaceuticals , Biotechnology , Earnings ,